FDA Inspection 1255905 — Zhejiang Huahai Pharmaceutical

Zhejiang Huahai Pharmaceutical — FEI 3003885745

The FDA completed an inspection of Zhejiang Huahai Pharmaceutical on Nov 20, 2024 in Linhai. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI)
End Date
Nov 20, 2024
Fiscal Year
2025
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Linhai (China)

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.